Steven Grant, MD, Virginia Commonwealth University
Steven Grant, MD
The Grant laboratory specializes on treatments or leukemia by targeting a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent. Their research is dedicated to cellular and molecular events that govern cancer cell behavior.
Products
References
- Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011 May 15;17(10):3219-32.
